meeting 18

DR. GUTMANN: We are blessed to have a great group of people presenting with expertise that is wide ranging in neuroscience, research, the ethics of neuroscience research and the ethics of the potential applications of the results of this research. And this is a unique opportunity for us as a Commission to hear from you. So give us one recommendation that you would like to see us, what we do in our report, whether it be what you want to make sure we attend to, something you think is really important for us to observe in the report.

SESSION 4: NEUROSCIENCE RESEARCH AND DIMINISHED CAPACITY

DR. GUTMANN: Great, this panel is going to revisit a topic that we discussed in our last meeting as well, and that is capacity to consent in research. And first we will hear from Dr. Jerry Menikoff, who is the director of the Office of Human Research Protections in the U.S. Department of Health and Human Services.

SESSION 3: NEUROSCIENCE RESEARCH—CLINICAL INNOVATION AND APPLICATIONS

DR. WAGNER: Welcome back everybody. I hope you enjoyed a good break over lunch. We are going to turn our attention now to clinical innovation and applications through neuroscience research. We are going to hear first ‑‑ same process, panelists. We are going to hear from each of you in rapid and fire sequence, and then have an opportunity to engage you with our questions from the panel.

SESSION 2: DIRECT-TO-CONSUMER NEUROTECHNOLOGY

DR. WAGNER:  Let me welcome all of our Commissioners back.  And who are we waiting for?  Steve.

DR. GUTMANN:  Let's just get started.  We can get started.  People will come very quickly when you ‑‑ once you get started.

DR. WAGNER:  Steve and John are out in the hallway.  And ‑‑ are they just chatting?  Here comes John.

DR. GUTMANN:  May I ask everybody to please take his or her seat?  Appreciate it.  We're going to get started.

Good morning.  I am Amy Gutmann.  I am President of the University of Pennsylvania, and I'm Chair of the Presidential Commission for the Study of Bioethical Issues.  And on behalf of myself and our Vice‑Chair Jim Wagner, who is the President of Emory University, I would like to welcome you to our 18th meeting.